医学
杜皮鲁玛
特应性皮炎
湿疹面积及严重程度指数
生活质量(医疗保健)
斯科拉德
哮喘
皮肤病科
不利影响
多中心研究
疾病
临床试验
疾病严重程度
儿科
皮肤科生活质量指数
回顾性队列研究
内科学
年轻人
过敏
梅德林
疾病负担
多中心试验
统计显著性
作者
María Fernanda Ordóñez,Laura Daniela Forero-Cortés,Natalia Vélez‐Tirado,Maribel Trujillo-Hernandez,Julián Esteban Londoño Hernández,Mauricio Torres-Pradilla,Elizabeth García,María Beatriz García-Paba,Mónica Paola Novoa,Karen Pinzón-Velasco,Mariana Botero-Varón,M. Z.,Lina María Castaño‐Jaramillo
摘要
Background Atopic dermatitis (AD) is a common chronic inflammatory skin disease in children, often preceding or coexisting with other atopic conditions. Severe AD significantly impacts quality of life and is associated with mental health disorders and sleep disturbances. Dupilumab is approved for moderate‐to‐severe AD in children aged 6 months and older. However, limited studies have evaluated its efficacy in diverse populations, especially in Latin American children. Methods We conducted a multicenter, retrospective study in Colombia, including children aged ≤ 18 years with moderate‐to‐severe AD who began dupilumab treatment between January 1, 2018, and January 1, 2024. Data collected included demographics, disease characteristics, treatment history, adverse events (AEs), and disease severity scores. Statistical analyses were performed using R software ( p < 0.05). Results Ninety‐two patients were included, with a median age of 14 years at dupilumab initiation. The most common comorbidities were allergic rhinitis (75%) and asthma (34%). Significant improvements in disease severity were observed, with a median reduction of 72% in EASI and 55% in SCORAD between Weeks 10 and 22, and 81% and 69%, respectively, by Weeks 46–58. Ocular AEs were the most frequent (23%), and paradoxical head and neck dermatitis occurred in 15% of patients. No serious AEs were reported, and 94% of patients remained on treatment. Conclusions Dupilumab showed significant clinical improvements in Latin American children with moderate‐to‐severe AD. AEs were mild and transient. These findings underscore the need for evaluating dupilumab’s efficacy in diverse populations for personalized treatment strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI